24/7 Market News Snapshot 20 March, 2025 – Eyenovia, Inc. Common Stock (NASDAQ:EYEN)

March 20, 2025

DENVER, Colo., 20 March, 2025 (247marketnews.com) – (NASDAQ:EYEN) are discussed in this article.
Eyenovia, Inc. (EYEN) has recently caught the attention of investors, trading at $1.799 during the pre-market session, marking a substantial gain of 7.72% from the previous day’s close of $1.670. The heightened trading volume of 3.57 million shares indicates increased investor interest, aligning with the observed upward price movement. This strong percentage shift reflects positive market sentiment and potential momentum for the stock. Technical indicators suggest that traders should monitor support levels for confirmation of the ongoing bullish trend, while resistance levels are likely to be tested in forthcoming sessions.

In addition to its stock performance, Eyenovia has announced a significant potential merger with Betaliq, Inc., aiming to transform the ophthalmic care landscape. This anticipated merger seeks to combine Eyenovia’s innovative Optejet device platform with Betaliq’s EyeSol® water-free drug delivery technology, specifically targeting glaucoma treatment.

Given that both companies possess FDA-approved technologies, the merger is expected to establish a formidable entity that can deliver advanced solutions for patients dealing with ocular diseases. If the merger is finalized, the new organization intends to continue marketing Eyenovia’s existing products while exploring additional licensing opportunities that could enhance revenue streams in the near future.

Eyenovia’s CEO, Michael Rowe, articulated the strategic importance of this collaboration, emphasizing its potential in enhancing the administration of topical eye medications for improved patient experience without compromising efficacy. Similarly, Betaliq’s CEO, Barry Butler, views this merger as a pivotal opportunity for innovation in patient care.

The transaction, which estimates Betaliq’s valuation at around $77 million and Eyenovia’s at $15 million, is contingent upon successful due diligence and definitive agreements. Eyenovia is on track for U.S. regulatory approval of its Optejet platform by the end of the year, marking significant potential growth and innovation in the ophthalmic sector, with further announcements expected in the upcoming weeks.

Related news for (EYEN)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.